Trump Administration to Announce Potential Link Between Tylenol Use During Pregnancy and Autism Risk

The Trump administration is set to announce a potential link between the use of acetaminophen, commonly known as Tylenol, during pregnancy and an increased risk of autism in children. This announcement is anticipated at a White House event on Monday, where President Donald Trump will be joined by Health and Human Services Secretary Robert F. Kennedy Jr. and other senior health officials.

The administration is also expected to highlight leucovorin, a form of folate, as a potential treatment for autism. Early trials have shown improvements in communication skills among children with autism who were administered leucovorin, though these studies are considered preliminary.

Medical guidelines currently consider acetaminophen safe for use during pregnancy. However, some studies have suggested a correlation between prenatal acetaminophen exposure and an increased risk of autism spectrum disorders and ADHD. Kenvue, the manufacturer of Tylenol, disputes these claims, stating that credible scientific evidence does not support a causal link between acetaminophen use and autism.

President Trump previewed the forthcoming announcement during a memorial service for conservative activist Charlie Kirk, stating, "I think we found an answer to autism."

Autism spectrum disorder is a neurodevelopmental condition characterized by challenges in social interaction, communication, and repetitive behaviors. The Centers for Disease Control and Prevention reports that autism diagnoses among 8-year-olds have increased from 0.66% in 2000 to 2.77% in 2020.

The administration's initiative has sparked debate within the scientific community, with some experts expressing concern over the potential implications of linking a widely used medication to autism risk. Further research is needed to establish any definitive causal relationships.